US · PRME · BIOTECHNOLOGY
Prime Medicine, Inc. (PRME) intrinsic value and stock valuation
$3.55as of 2026-11-21 · Mkt cap 556.3M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Prime Medicine, Inc. DCF and intrinsic value
InvestorsCraft values PRME with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRME’s statements →
Prime Medicine, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2019–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Septerna Inc (SEPN) $38.61
- Tyra Biosciences, Inc. (TYRA) $20.12
- Bicara Therapeutics Inc. Common Stock (BCAX) $8.44
- Vir Biotechnology, Inc. (VIR) $8.39
- EyePoint Pharmaceuticals, Inc. (EYPT) $0.23
- Replimune Group, Inc. (REPL) $19.07
- Maravai LifeSciences Holdings, Inc. (MRVI) $6.98
- Kura Oncology, Inc. (KURA) $6.91
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.63M | $2.98M | $0.00 | $0.00 | $0.00 |
| Operating income | -$-208.35M | -$-202.47M | -$-204.79M | -$-116.54M | -$-84.47M |
| Net income | -$-201.14M | -$-195.88M | -$-198.13M | -$-121.82M | -$-165.37M |
| EPSd | -$-1.35M | -$-1.65M | -$-2.18M | -$-1.25M | -$-1.73M |
| Operating cash flow | -$-162.56M | -$-122.86M | -$-165.41M | -$-131.83M | -$-34.08M |
| Capital expenditure | -$-4.53M | -$-7.29M | -$-8.72M | -$-16.09M | -$-4.15M |
| Free cash flow | -$-167.09M | -$-130.16M | -$-174.14M | -$-147.92M | -$-38.23M |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M | $301.9M |
| Total debt | $116.4M | $40.8M | $13.6M | $28.8M | $10.4M |
| Net debt | $53.4M | -$-141.68M | -$-27.94M | -$-158.88M | -$-175.01M |
| Total equity | $120.9M | $153.2M | $133.1M | $316.3M | $239.6M |
| Cash and short-term investments | $177.7M | $190.4M | $121.7M | $293.9M | $269.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.63M | $2.98M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $7.32M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-2.69M | $2.98M | $0.00 | $0.00 | $0.00 |
| Research and development expenses | $160.6M | $155.3M | $147.9M | $86.7M | $70.6M |
| Selling, general and administrative expenses | $52.4M | $50.2M | $43.4M | $29.8M | $13.9M |
| Other expenses | -$-7.32M | $0.00 | $13.5M | $0.00 | $0.00 |
| Operating expenses | $205.7M | $205.5M | $204.8M | $116.5M | $84.5M |
| Cost and expenses | $213M | $205.5M | $204.8M | $116.5M | $84.5M |
| Interest income | $4.15M | $3.52M | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $5.38M | $6.13M | $4.65M | $2.22M | $570K |
| Ebitda | -$-195.76M | -$-189.75M | -$-186.64M | -$-120.55M | -$-165.28M |
| Operating income | -$-208.35M | -$-202.47M | -$-204.79M | -$-116.54M | -$-84.47M |
| Total other income/expenses, net | $7.21M | $6.58M | $6.38M | -$-6.22M | -$-81.38M |
| Income before tax | -$-201.14M | -$-195.88M | -$-198.41M | -$-122.77M | -$-165.85M |
| Income tax expense | $0.00 | $0.00 | -$-280K | -$-950K | -$-490K |
| Net income | -$-201.14M | -$-195.88M | -$-198.13M | -$-121.82M | -$-165.37M |
| Weighted average shares outstanding | $148.8M | $118.6M | $91M | $97.2M | $95.7M |
| Weighted average diluted shares outstanding | $148.8M | $118.6M | $91M | $97.2M | $95.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $177.7M | $190.4M | $121.7M | $293.9M | $269.6M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $181.3M | $211.9M | $143M | $296.6M | $270.6M |
| Property, plant and equipment, net | $146.8M | $71.6M | $36.6M | $48.6M | $15.7M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $161.4M | $85.6M | $50.9M | $63.7M | $31.3M |
| Total assets | $342.7M | $297.5M | $193.9M | $360.3M | $301.9M |
| Accounts payable | $8.89M | $11.4M | $19.5M | $4.33M | $1.44M |
| Short-term debt | $8.14M | $3.61M | $9.28M | $11.7M | $7.34M |
| Deferred revenue | $7.82M | $7.09M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $37.5M | $38M | $56.4M | $26.7M | $58M |
| Long-term debt | $108.3M | $37.2M | $4.36M | $17.1M | $3.07M |
| Deferred revenue, non-current | $0.00 | $63.2M | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $184.4M | $106.4M | $4.36M | $17.3M | $4.31M |
| Capital lease obligations | $8.14M | $40.8M | $13.6M | $28.8M | $10.4M |
| Total liabilities | $221.9M | $144.4M | $60.8M | $44M | $62.3M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-888.35M | -$-687.21M | -$-491.33M | -$-293.2M | -$-171.38M |
| Accumulated other comprehensive income (loss) | $80K | $0.00 | -$-10K | -$-380K | -$-30K |
| Total equity | $120.9M | $153.2M | $133.1M | $316.3M | $239.6M |
| Total investments | $114.7M | $7.97M | $80.1M | $106.3M | $84.2M |
| Total debt | $116.4M | $40.8M | $13.6M | $28.8M | $10.4M |
| Net debt | $53.4M | -$-141.68M | -$-27.94M | -$-158.88M | -$-175.01M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-201.14M | -$-195.88M | -$-198.13M | -$-121.82M | -$-165.37M |
| Depreciation and amortization | $5.38M | $6.13M | $4.65M | $2.22M | $570K |
| Stock-based compensation | $29.3M | $26.1M | $13.9M | $6.46M | $1.75M |
| Change in working capital | -$-5.34M | $31.1M | $2.65M | -$-35.4M | $31.2M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $1M | -$-5.26M | $9.14M | $2.46M | $1.19M |
| Net cash provided by operating activities | -$-162.56M | -$-122.86M | -$-165.41M | -$-131.83M | -$-34.08M |
| Investments in property, plant and equipment | -$-4.53M | -$-7.29M | -$-8.72M | -$-16.09M | -$-4.15M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-108.76M | $68.5M | $18.7M | -$-47.1M | -$-73.63M |
| Common stock issued | $139.5M | $170.1M | $660K | $185.3M | $270.4M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $151.5M | $195.9M | $660K | $181.5M | $269.3M |
| Net change in cash | -$-119.81M | $141.5M | -$-146.05M | $2.57M | $161.6M |
| Cash at end of period | $76.7M | $196.5M | $55.1M | $201.1M | $198.5M |
| Operating cash flow | -$-162.56M | -$-122.86M | -$-165.41M | -$-131.83M | -$-34.08M |
| Capital expenditure | -$-4.53M | -$-7.29M | -$-8.72M | -$-16.09M | -$-4.15M |
| Free cash flow | -$-167.09M | -$-130.16M | -$-174.14M | -$-147.92M | -$-38.23M |
Line items
Line items
Line items
About Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
- CEO
- Allan Reine
- Employees
- 146
- Beta
- 2.27
Explore
Frequently asked questions
What is the intrinsic value of Prime Medicine, Inc. (PRME)?
Prime Medicine, Inc. (PRME) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PRME undervalued?
PRME trades at a price of $3.55 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.